Coverage was initially denied because the plaintiff never "held" the funds.

The commercialization of cell and gene therapies raises several complex conversations and questions for employers and payers.

A review of 1,000 hospitals by Patient Rights Advocate found that only 14% were fully complying with the rule.

By using advanced technology, data and analytics, it becomes much more feasible to look at leading causes of high-frequency and high-cost claims and consider plans that address them.